Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041938 · ClinicalTrials.gov registry record · Phase 3
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
A Phase 3 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,305
- Enrollment target
NCT00041938: Completed Phase 3 study, sponsored by Columbia University.
NCT00041938 is a Phase 3 study that has completed, run by Columbia University. The registered enrollment target is 2,305 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (199% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00041938, a Phase 3 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,305 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function. We are now transitioning into the sub-analysis part of the WARCEF patient data. The study has recently completed data analysis for its Primary Aim. All randomized patients have completed their follow up. All study related procedure as per the protocol has been completed. We are now in the extension phase of the study to obtain more patient data to address further aims of the study. No new procedures are performed and data already in place at the sites will be collected (EKG and echocardiograms). The aims for this study extension are: * To assess progression of cardiac dysfunction over time among heart failure patients * To correlate prognosis with cardiac dysfunction
Primary Outcome
The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100\*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.
Interventions
- DRUG Warfarin
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,305 participants |
| Start Date | 2002-10 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
What the finished NCT00041938 record still lists
NCT00041938 is an interventional study that assigns participants to a tested intervention. Its 2,305 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (199% higher).
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00041938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00041938 about?
NCT00041938 is a clinical study titled "Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial". The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function. We are now transitioning into the sub-analysis part of the WARCEF patient data. The study has recently completed data analysis for...
What is the current status of trial NCT00041938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,305 participants. The study started on 2002-10. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00041938?
The interventions under investigation include: Warfarin (DRUG), aspirin (DRUG).
Who is sponsoring clinical trial NCT00041938?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00041938's enrollment target sits among peer trials
2,305 94th of 2000 higher than 1,907 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05485961 · 2,310 participants · Phase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- NCT05732623 · 2,300 participants
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia